điều trị loãng xương cho phụ nữ mãn kinh

X
2019

Tri Ph
BON CON 003_27-06-


guideline
2

gia

n
ph


cao

trung
NC
NC

NC
sai

NC quan

NC quan

4*

3*

2*

1*

4*

3*

2*

1*

t

Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrin Society Clinical Practice Guideline


x
T socre

-2.5

-

-1.0

-

score

x
x

ph

x

x

x

x

th

th

DEXA
l ng

Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrin Society Clinical Practice Guideline


x
x

gia

o Frax
o Nguyen

x
o
o Trung
o Cao
Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrin Society Clinical Practice Guideline


x
Nguy
cao

Nguy

- 2.5

cao

- 2.5

theo Frax
Nguy

trung

-

Nguy

-1.0

-

(-)

(-)

3%

3%

20%

20%

x
Nguy
x

20%

H


Pharmacological Management of Osteoporosis in Postmenopausal Women: An EndocrinSociety Clinical Practice Guideline


x

Ch a

x

x

Pharmacological Management of Osteoporosis in Postmenopausal Women: An EndocrinSociety Clinical Practice Guideline

sau 2


x

Pharmacological Management of Osteoporosis in Postmenopausal Women: An EndocrinSociety Clinical Practice Guideline

trung


ai
x

cao
x
4*

Pharmacological Management of Osteoporosis in Postmenopausal Women: An EndocrinSociety Clinical Practice Guideline


x

cao

Biphosphonate: 4*
o Zoledronate, alendronate, risedronate, ibandronate

Denosumab: 4*
3*
o Teriparatide, abaloparatide

Pharmacological Management of Osteoporosis in Postmenopausal Women: An EndocrinSociety Clinical Practice Guideline


Biphosphonate (4*)
x


Denosumab (4*)
x

Pharmacological Management of Osteoporosis in Postmenopausal Women: An EndocrinSociety Clinical Practice Guideline


Denosumab (4*)
Ng ng denosumab
o
o
o
o

x

giai

nhanh
holiday
x
x

Pharmacological Management of Osteoporosis in Postmenopausal Women: An EndocrinSociety Clinical Practice Guideline

sau 5-10

(1*)


Teriparatide and Abaloparatide (PTH and

x
x
(2*)

Pharmacological Management of Osteoporosis in Postmenopausal Women: An EndocrinSociety Clinical Practice Guideline

duy


Teriparatide and Abaloparatide (3*)
x

Pharmacological Management of Osteoporosis in Postmenopausal Women: An EndocrinSociety Clinical Practice Guideline

Pharmacological Management of Osteoporosis in Postmenopausal Women: An EndocrinSociety Clinical Practice Guideline


SERM (4*)

Pharmacological Management of Osteoporosis in Postmenopausal Women: An EndocrinSociety Clinical Practice Guideline


(3)
biphosphonate,desonumab
D 60

tim, ung th

Pharmacological Management of Osteoporosis in Postmenopausal Women: An EndocrinSociety Clinical Practice Guideline


(3*)

Pharmacological Management of Osteoporosis in Postmenopausal Women: An EndocrinSociety Clinical Practice Guideline


calcitonin (1)

Pharmacological Management of Osteoporosis in Postmenopausal Women: An EndocrinSociety Clinical Practice Guideline


Calcium

vitamin D (1)

x

x

Calcium
o

nguy

x

Vitamin D
o

nguy

x

Vitamin D + calcium
o
o

nguy

x
x

Pharmacological Management of Osteoporosis in Postmenopausal Women: An EndocrinSociety Clinical Practice Guideline

19%
5%


Biphosphonate 3
sau khi
ng ng
So
o
o
x

Pharmacological Management of Osteoporosis in Postmenopausal Women: An EndocrinSociety Clinical Practice Guideline


AFF,
nguy
holidays

x
o
o
o

x
80%
nguy

o

Pharmacological Management of Osteoporosis in Postmenopausal Women: An EndocrinSociety Clinical Practice Guideline

x
x

2-4


T
H
A
N
K
Y
O
U